Where Merck KGAA’s Pipeline Stands
Executive Summary
Pipeline review resulted in new focus and products with high value, exec explains.
You may also be interested in...
On The Threshold Of The Tumor Microenvironment
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.
Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.